|Positive WB detected in||HepG2 cells, HL-60 cells, human placenta tissue|
|Positive IP detected in||HL-60 cells|
|Positive IF detected in||NCCIT cell|
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
10828-1-AP targets c-MYC in WB, IP, IF, FC, CoIP, chIP,ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, pig, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||c-MYC fusion protein Ag1263|
|Full Name||v-myc myelocytomatosis viral oncogene homolog (avian)|
|Calculated molecular weight||49 kDa|
|Observed molecular weight||62-65 kDa, 50 kDa|
|GenBank accession number||BC000141|
|Gene ID (NCBI)||4609|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
c-Myc (also known as Myc), together with l-Myc and n-Myc, belongs to the Myc family of transcription factors. c-Myc has a basic helix-loop-helix leucine zipper domain and through heterodimerization can bind and regulate the transcriptional activity of genes, either by repression or activation. It is a key player in the regulation of cell growth and cell cycle progression and acts as a proto-oncogene.
c-Myc is ubiquitously expressed in almost all cell types and its expression positively correlates with tissue proliferative capacity. c-Myc is also expressed during embryogenesis and is upregulated in many cancer types.
Involvement in disease
· Upregulated in many cancer types, especially in aggressive, poorly differentiated tumors.
· Mutations in the MYC gene and breakpoint translocations within the MYC gene cause Burkitt lymphoma.
There are 3 different isoforms of c-Myc: c-Myc1, c-Myc2, and c-MycS (PMID: 16260605). They differ in molecular size, can be preferentially expressed during cell growth, and are reported to be functionally distinct.
c-Myc is subject to various post-translational modifications, including phosphorylation, acetylation, and ubiquitinylation (PMID: 16987807), which regulate its activity.
c-Myc localizes to the nucleus but can also be present in the cytoplasm of certain cancer types.
|Product Specific Protocols|
|WB protocol for c-MYC antibody 10828-1-AP||Download protocol|
|IF protocol for c-MYC antibody 10828-1-AP||Download protocol|
|IP protocol for c-MYC antibody 10828-1-AP||Download protocol|
|FC protocol for c-MYC antibody 10828-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Stem Cell Res Ther
Exosomes from glioma cells induce a tumor-like phenotype in mesenchymal stem cells by activating glycolysis.
Clin Sci (Lond)
J Exp Clin Cancer Res
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
A novel tumor suppressor SPINK5 targets Wnt/β-catenin signaling pathway in esophageal cancer.
ACS Appl Mater Interfaces
ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
Anna-Maria (Verified Customer) (08-13-2019)
This antibody worked as expected for western blotting
Christine (Verified Customer) (11-13-2018)
The antibody worked better than the Abcam c-Myc antibody. However, I did not get clear nuclear staining but rather a mix of nuclear staining with cytoplasmic staining. This could be due non-optimized conditions.
Claudio (Verified Customer) (12-14-2017)
We tested the antibody in IHC/IFL on mouse brain tumors that showed c-myc upregulation at the mRNA level.